June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Suppressive effects of 17β-estradiol on immortalized human meibomian gland epithelial cells
Author Affiliations & Notes
  • Wendy Kam
    Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
  • David Sullivan
    Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
  • Footnotes
    Commercial Relationships Wendy Kam, None; David Sullivan, Forest Research Institute (C), Horus Pharma (R), TearLab (S), Lubris (I), Santen (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4316. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wendy Kam, David Sullivan; Suppressive effects of 17β-estradiol on immortalized human meibomian gland epithelial cells. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4316.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Previous studies have shown that 17β-estradiol (E2) significantly decreases adenylate cyclase activity in bone cells, thereby attenuating the cyclic AMP response to stimulatory factors (e.g. the secretagogue forskolin). It is possible that this inhibitory effect on signal transduction represents one mechanism by which estrogens suppress sebaceous gland epithelial cell function. If so, such an E2 influence on the meibomian gland, which is a large sebaceous gland, could account for the increased incidence of dry eye disease in women taking estrogen replacement therapy. Our objective was to determine whether E2 attenuates secretagogue-induced cAMP accumulation in immortalized human meibomian gland epithelial cells (iHMGEC). As part of these studies, we also evaluated whether E2 modulates iHMGEC proliferation.

Methods: Immortalized human meibomian gland epithelial cells were cultured in medium free of serum and phenol red prior to treatment. For cAMP analysis, cells were treated with E2 (100 pM), forskolin (100 µM), the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX; 1 mM), or buffer for 10 minutes prior to quantification of intracellular cAMP with a colorimetric enzyme-linked immunoassay. For proliferation studies, cells exposed to E2 or buffer for 1, 3, and 5 days were counted with a hemocytometer.

Results: Estrogen treatment caused a significant decrease in secretagogue-induced cAMP accumulation in iHMGEC. This hormonal effect was observed after cellular exposure to either forskolin or IBMX. In contrast, in the absence of E2, forskolin and IBMX elicited rapid intracellular cAMP accumulation. Treatment of iHMGEC with E2 for 5 days caused a slight but significant decrease in proliferation.

Conclusions: Our research demonstrates that E2 may suppress both cAMP signaling in, and the proliferation of, iHMGEC. The mechanisms underlying these estrogen effects, as well as their possible role in promoting dry eye, remain to be clarified.

Keywords: 486 cornea: tears/tear film/dry eye  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×